4//SEC Filing
Wallace Max N. 4
Accession 0001104659-21-110531
CIK 0001818382other
Filed
Aug 26, 8:00 PM ET
Accepted
Aug 27, 4:10 PM ET
Size
11.9 KB
Accession
0001104659-21-110531
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Wallace Max N.
Director
Transactions
- Award
Stock Options (right to buy)
2021-08-26+6,564→ 6,564 totalExercise: $1.19Exp: 2023-11-22→ Common Stock (6,564 underlying) - Award
Common Stock
2021-08-26+49,986→ 49,986 total - Award
Stock Options (right to buy)
2021-08-26+13,129→ 13,129 totalExercise: $2.56Exp: 2025-09-01→ Common Stock (13,129 underlying) - Award
Stock Options (right to buy)
2021-08-26+17,068→ 17,068 totalExercise: $6.54Exp: 2028-04-12→ Common Stock (17,068 underlying)
Footnotes (3)
- [F1]On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc.
- [F2]Options are fully vested and exercisable.
- [F3]As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.
Documents
Issuer
Humacyte, Inc.
CIK 0001818382
Entity typeother
Related Parties
1- filerCIK 0001877453
Filing Metadata
- Form type
- 4
- Filed
- Aug 26, 8:00 PM ET
- Accepted
- Aug 27, 4:10 PM ET
- Size
- 11.9 KB